Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 33.3% in December

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 23,200 shares, a growth of 33.3% from the December 15th total of 17,400 shares. Based on an average daily trading volume, of 63,600 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.1% of the company's stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Kamada in a report on Friday, January 10th.

Institutional Trading of Kamada

An institutional investor recently bought a new position in Kamada stock. Plato Investment Management Ltd purchased a new stake in Kamada Ltd. (NASDAQ:KMDA - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,785 shares of the biotechnology company's stock, valued at approximately $117,000. Institutional investors own 20.38% of the company's stock.

Kamada Price Performance

KMDA stock traded down $0.15 during trading hours on Thursday, reaching $7.09. The stock had a trading volume of 79,532 shares, compared to its average volume of 245,554. The stock has a 50-day simple moving average of $6.16 and a 200 day simple moving average of $5.74. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $8.00. The stock has a market capitalization of $407.53 million, a PE ratio of 25.32 and a beta of 0.98.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.